FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 08/2024 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 08/2024”.

The Monitor is a monthly published overview of venture capital trends in the US Healthcare & Life Sciences sector.

As of the end of August 2024 we identified the following current VC trends in the United States:

• Total Healthcare & Life Sciences funding reached EUR 25,225m
• Biotech received 53% of the total investment volume (EUR 13,281m) with oncology being the leading indication (27%)
• In August Caresyntax secures the highest transaction volume with EUR 285m, followed by Halda Therapeutics with EUR 163m and IDRx with EUR 110m
• RA Capital Management (United States) is the most active investor (by deal volume), followed by ARCH Venture Partners (United States) and F-Prime Capital (United States)

To access the full report, please click here.